Jim Nonomiya

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 176 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Daniel P. Sutherlin, Deepak Sampath, Megan Berry et al. · Journal of Medicinal Chemistry · 2010 · 131 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure of the Catalytic Domain of Human Polo-like Kinase 1^,

Michael Kothe, Darcy Kohls, Simon Low et al. · Biochemistry · 2007 · 123 citations

Life Sciences, Molecular Biology, Oncology +13